A Phase 2 interventional study of eculizumab and Placebo in Myasthenia Gravis, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 25 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-09-24.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Myasthenia Gravis by AstraZeneca — 8 open to participants now, 11 under way, 4 of them phase 3. Myasthenia Gravis · AstraZeneca.
Among the 19 studies in Myasthenia Gravis by AstraZeneca, this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2008, is one of 3 in phase 2, and was the 1st registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →8 of the 19 studies in Myasthenia Gravis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
Alexion Pharmaceuticals, Inc. · Sites in China
Ages 18–130
Alexion Pharmaceuticals, Inc. · Sites in United States, Germany, Italy and 1 more country
Ages 18+
AstraZeneca · Sites in Russia
Ages 18+
Alexion Pharmaceuticals, Inc. · Sites in Italy
Ages 18+
AstraZeneca · Sites in Poland
Ages 18+
By country, each count listing its studies:
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2008.
This study's enrollment of 14 is below the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 20 across the 13 interventional studies, 263 across the 6 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
4 of the studies in Myasthenia Gravis by AstraZeneca that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607627Phase 3Alexion Pharmaceuticals, Inc.PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | 2026-12-15 |
| NCT07596784Phase 3Alexion Pharmaceuticals, Inc.Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) | 2027-08-24 |
| NCT06967480Alexion Pharmaceuticals, Inc.Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis | 2027-06-30 |
| NCT07221838Alexion Pharmaceuticals, Inc.A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab | 2027-08-27 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Myasthenia Gravis by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of patients with generalized myasthenia gravis despite treatment with various immunosuppressants, such as prednisone, methotrexate, Cellcept, cyclosporine, and cyclophosphamide, that are currently available.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
eculizumab
Drug: eculizumab
Placebo
Drug: Placebo
eculizumab 600 mg IV weekly for 4 doses followed by eculizumab 900 mg IV every two weeks for 7 doses
Also known as: Soliris
Placebo IV weekly for 4 doses then every two weeks for 7 doses
Quantitative Myasthenia Gravis (QMG): The Primary Efficacy Endpoint in This Study Was the Percentage of Patients With a 3-point Reduction From Baseline in the QMG Total Score for Disease Severity.
The QMG scoring system is considered to be an objective evaluation of muscle strength based on quantitative testing of sentinel muscle groups. The MGFA task force has recommended that the QMG score be used in prospective studies of therapy for MG.
Time frame: 16 weeks
Mean Change From Baseline in QMG Total Score
The QMG scoring system is considered to be an objective evaluation of muscle strength based on quantitative testing of sentinel muscle groups. The Myasthenia Gravis Foundation of America task force has recommended that the QMG score be used in prospective studies of therapy for MG. The QMG scoring system consists of 13 items. Each item is graded 0 to 3, with 3 being the most severe. The range of total QMG score is 0-39.
Time frame: 16 weeks
Change From Baseline in the MGFA Post-Intervention Status (PIS)
The MGFA PIS is designed to assess the clinical state of MG patients at any time after treatment of MG is initiated. Change in status categories of Improved, Unchanged, Worse, Exacerbation, and Died of MG was to be assessed and recorded at every visit from Visits 3 to 24 (Weeks 1 to 16). Minimal manifestations were to be assessed at these visits.
Time frame: 16 weeks
Change From Baseline in the MG-Activity of Daily Living Profile (MG-ADL)
The MG-ADL is an 8-point questionnaire that focuses on relevant symptoms and functional performance of activities of daily living (ADL) in MG patients. The 8 items of the MG-ADL were derived from symptom-based components of the original 13-item QMG to assess disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. In this functional status instrument, each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL score is 0 - 24. MG-ADL was to be performed at every study visit. The recall period for MG-ADL was since the preceding study visit (1 or 2 weeks).
Time frame: 16 weeks
Change From Baseline in the QoL Instrument, SF-36.
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (physical functioning, role-physical, bodily pain, general health, mental health, role-emotional, social functioning and vitality) as well as psychometrically-based physical and mental health summary measures. It is a generic measure, as opposed to one that targets a specific age, disease or treatment group. The lower the score the more disability; the higher the score the less disability. Norm-based scoring involving a linear T-score transformation method was used so that scores for each of the health domain scales and component summary measures have a mean of 50 and a standard deviation of 10 based on the 1998 US general population. Thus, scores above and below 50 are above and below the average, respectively, in the 1998 US general.
Time frame: 16 weeks
Change From Baseline in Respiratory Function Tests to Characterize the Degree of Involvement of Respiratory Muscles.
Change from Baseline in Forced Vital Capacity
Time frame: 16 weeks
Change From Baseline in Respiratory Function Tests to Characterize the Degree of Involvement of Respiratory Muscles.
Change from Baseline in Negative Inspiratory Force. NIF is a measurement of respiratory muscle strength and ventilator reserve. NIF is represented by centimeters of water pressure (cmH2O). A normal NIF measurement is negative 60 cmH2O, or as 100% predicted value.
Time frame: 16 weeks
Change From Baseline to the End of Treatment (16 Weeks) in the Two Most Affected QMG Items for Disease Severity (Individual Test Item: Double Vision)
The QMG scoring system is considered to be an objective evaluation of muscle strength based on quantitative testing of sentinel muscle groups. The MGFA task force has recommended that the QMG score be used in prospective studies of therapy for MG. All individual QMG items are scored 0 to 3, with 3 being the most severe. Negative values imply an improvement in QMG Item Score.
Time frame: 16 weeks
Change From Baseline to the End of Treatment (16 Weeks) in the Two Most Affected QMG Items for Disease Severity (Individual Test Item: Ptosis)
The QMG scoring system is considered to be an objective evaluation of muscle strength based on quantitative testing of sentinel muscle groups. The MGFA task force has recommended that the QMG score be used in prospective studies of therapy for MG. All individual QMG items are scored 0 to 3, with 3 being the most severe. Negative values imply an improvement in QMG Item Score.
Time frame: 16 weeks
There were 26 IRB/IEC-approved study sites. Patients were screened at 13 Institutional Review Board/Independent Ethics Committee approved study sites; and 14 patients were randomized at 8 sites.
| Milestone | Eculizumab to Placebo Sequence | Placebo to Eculizumab Sequence | Not Randomized/Screen Failures |
|---|---|---|---|
| Started | 7 | 7 | 16 |
| Completed | 7 | 7 | 0 |
| Not completed | 0 | 0 | 16 |
| Withdrew: Low qmg scores | 0 | 0 | 6 |
| Withdrew: Lacked achr antibodies | 0 | 0 | 5 |
| Withdrew: Not stable on concomitant mg therapy | 0 | 0 | 2 |
| Withdrew: Severe infections | 0 | 0 | 2 |
| Withdrew: History of thymoma | 0 | 0 | 1 |
| Milestone | Eculizumab to Placebo Sequence | Placebo to Eculizumab Sequence | Not Randomized/Screen Failures |
|---|---|---|---|
| Started | 7 | 7 | 0 |
| Completed | 7 | 7 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Eculizumab to Placebo Sequence | Placebo to Eculizumab Sequence | Not Randomized/Screen Failures |
|---|---|---|---|
| Started | 7 | 7 | 0 |
| Completed | 7 | 7 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Eculizumab to Placebo Sequence | Placebo to Eculizumab Sequence | Not Randomized/Screen Failures |
|---|---|---|---|
| Started | 6 | 6 | 0 |
| Completed | 6 | 5 | 0 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
The QMG scoring system is considered to be an objective evaluation of muscle strength based on quantitative testing of sentinel muscle groups. The MGFA task force has recommended that the QMG score be used in prospective studies of therapy for MG.
| percentage of patients | Eculizumab Period 1 | Placebo Period 1 |
|---|---|---|
| Quantitative Myasthenia Gravis (QMG): The Primary Efficacy Endpoint in This Study Was the Percentage of Patients With a 3-point Reduction From Baseline in the QMG Total Score for Disease Severity. | 86 | 57 |
The QMG scoring system is considered to be an objective evaluation of muscle strength based on quantitative testing of sentinel muscle groups. The Myasthenia Gravis Foundation of America task force has recommended that the QMG score be used in prospective studies of therapy for MG. The QMG scoring system consists of 13 items. Each item is graded 0 to 3, with 3 being the most severe. The range of total QMG score is 0-39.
| units on a scale | Eculizumab Period 1 | Placebo Period 1 | Eculizumab Both Periods | Placebo Both Periods |
|---|---|---|---|---|
| Mean Change From Baseline in QMG Total Score | -7.43 ± 5.563 | -2.71 ± 4.855 | -7.92 ± 5.054 | -3.67 ± 4.008 |
The MGFA PIS is designed to assess the clinical state of MG patients at any time after treatment of MG is initiated. Change in status categories of Improved, Unchanged, Worse, Exacerbation, and Died of MG was to be assessed and recorded at every visit from Visits 3 to 24 (Weeks 1 to 16). Minimal manifestations were to be assessed at these visits.
| participants | Eculizumab Period 1 | Placebo Period 1 | Eculizumab Period 2 | Placebo Period 2 |
|---|---|---|---|---|
| Improved | 5 | 6 | 6 | 2 |
| Unchanged | 2 | 1 | 0 | 4 |
| Worse | 0 | 0 | 0 | 0 |
| Exacerbation | 0 | 0 | 0 | 0 |
| Died of MG | 0 | 0 | 0 | 0 |
The MG-ADL is an 8-point questionnaire that focuses on relevant symptoms and functional performance of activities of daily living (ADL) in MG patients. The 8 items of the MG-ADL were derived from symptom-based components of the original 13-item QMG to assess disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. In this functional status instrument, each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL score is 0 - 24. MG-ADL was to be performed at every study visit. The recall period for MG-ADL was since the preceding study visit (1 or 2 weeks).
| units on a scale | Eculizumab Period 1 | Placebo Period 1 | Eculizumab Both Periods | Placebo Both Periods |
|---|---|---|---|---|
| Change From Baseline in the MG-Activity of Daily Living Profile (MG-ADL) | 4.29 ± 1.799 | 7.86 ± 3.716 | 5.42 ± 3.315 | 7.00 ± 3.464 |
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (physical functioning, role-physical, bodily pain, general health, mental health, role-emotional, social functioning and vitality) as well as psychometrically-based physical and mental health summary measures. It is a generic measure, as opposed to one that targets a specific age, disease or treatment group. The lower the score the more disability; the higher the score the less disability. Norm-based scoring involving a linear T-score transformation method was used so that scores for each of the health domain scales and component summary measures have a mean of 50 and a standard deviation of 10 based on the 1998 US general population. Thus, scores above and below 50 are above and below the average, respectively, in the 1998 US general.
| units on a scale | Eculizumab Period 1 | Placebo Period 1 | Eculizumab Both Periods | Placebo Both Periods |
|---|---|---|---|---|
| Physical Functioning (Last Visit) | 56.43 ± 29.255 | 64.29 ± 24.054 | 57.92 ± 26.921 | 57.08 ± 27.507 |
| Role Physical (Last Visit) | 61.61 ± 38.600 | 68.75 ± 25.769 | 64.06 ± 31.771 | 60.94 ± 27.324 |
| Bodily Pain (Last Visit) | 60.00 ± 24.235 | 74.86 ± 20.651 | 66.75 ± 22.511 | 76.17 ± 15.689 |
| General Health (Last Visit) | 47.86 ± 16.994 | 40.43 ± 23.201 | 44.67 ± 16.267 | 37.50 ± 19.365 |
| Vitality (Last Visit) | 50.00 ± 23.936 | 52.68 ± 15.670 | 53.13 ± 19.310 | 48.96 ± 18.238 |
| Social Functioning (Last Visit) | 66.07 ± 25.733 | 82.14 ± 17.466 | 66.67 ± 24.034 | 78.13 ± 17.778 |
| Role Emotional (Last Visit) | 77.38 ± 36.233 | 71.43 ± 29.603 | 70.83 ± 34.542 | 82.64 ± 25.981 |
| Mental Health (Last Visit) | 76.43 ± 17.728 | 58.57 ± 25.284 | 69.17 ± 20.542 | 68.75 ± 23.270 |
| Physical Component Score (Last Visit) | 38.73 ± 10.235 | 44.97 ± 7.721 | 41.40 ± 8.591 | 40.32 ± 10.025 |
| Mental Component Score (Last Visit) | 49.50 ± 12.066 | 43.95 ± 12.530 | 46.11 ± 12.596 | 49.03 ± 11.476 |
Change from Baseline in Forced Vital Capacity
| percentage of predicted | Eculizumab Period 1 | Placebo Period 1 | Eculizumab Both Periods | Placebo Both Periods |
|---|---|---|---|---|
| Change From Baseline in Respiratory Function Tests to Characterize the Degree of Involvement of Respiratory Muscles. | 76.43 ± 15.328 | 87.00 ± 23.544 | 80.00 ± 14.894 | 76.75 ± 23.152 |
Change from Baseline in Negative Inspiratory Force. NIF is a measurement of respiratory muscle strength and ventilator reserve. NIF is represented by centimeters of water pressure (cmH2O). A normal NIF measurement is negative 60 cmH2O, or as 100% predicted value.
| percentage of predicted | Eculizumab Period 1 | Placebo Period 1 | Eculizumab Both Periods | Placebo Both Periods |
|---|---|---|---|---|
| Change From Baseline in Respiratory Function Tests to Characterize the Degree of Involvement of Respiratory Muscles. | 92.43 ± 13.464 | 99.00 ± 2.646 | 93.50 ± 12.087 | 93.50 ± 12.042 |
The QMG scoring system is considered to be an objective evaluation of muscle strength based on quantitative testing of sentinel muscle groups. The MGFA task force has recommended that the QMG score be used in prospective studies of therapy for MG. All individual QMG items are scored 0 to 3, with 3 being the most severe. Negative values imply an improvement in QMG Item Score.
| units on a scale | Eculizumab | Placebo |
|---|---|---|
| Change From Baseline to the End of Treatment (16 Weeks) in the Two Most Affected QMG Items for Disease Severity (Individual Test Item: Double Vision) | -0.71 ± 1.113 | -0.29 ± 0.488 |
The QMG scoring system is considered to be an objective evaluation of muscle strength based on quantitative testing of sentinel muscle groups. The MGFA task force has recommended that the QMG score be used in prospective studies of therapy for MG. All individual QMG items are scored 0 to 3, with 3 being the most severe. Negative values imply an improvement in QMG Item Score.
| units on a scale | Eculizumab | Placebo |
|---|---|---|
| Change From Baseline to the End of Treatment (16 Weeks) in the Two Most Affected QMG Items for Disease Severity (Individual Test Item: Ptosis) | -1.00 ± 1.155 | -0.5 ± 1.000 |
Collected over 46 weeks (Screening Period [up to 4 weeks], Treatment Period 1 [16 weeks], Washout Period [5 weeks], Treatment Period 2 [16 weeks], Follow-up Period [5 weeks]) for adverse events (AEs); 42 weeks for treatment emergent AEs (TEAEs).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/13 (7.7%) | 11/13 (84.6%) |
| Eculizumab | — | 1/13 (7.7%) | 13/13 (100%) |
| Event | Placebo | Eculizumab |
|---|---|---|
| Myasthenia GravisNervous system disorders | 0/13 | 1/13 |
| Myasthenia Gravis CrisisNervous system disorders | 1/13 | 0/13 |
| Event | Placebo | Eculizumab |
|---|---|---|
| NauseaBlood and lymphatic system disorders | 2/13 | 4/13 |
| Back PainMusculoskeletal and connective tissue disorders | 1/13 | 4/13 |
| HeadacheNervous system disorders | 4/13 | 3/13 |
| NasopharyngitisInfections and infestations | 2/13 | 3/13 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/13 | 3/13 |
| Neck PainMusculoskeletal and connective tissue disorders | 1/13 | 3/13 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/13 | 3/13 |
| ConstipationGastrointestinal disorders | 0/13 | 2/13 |
| FatigueGeneral disorders | 1/13 | 2/13 |
| InfluenzaInfections and infestations | 0/13 | 2/13 |
| Age, Continuous(years) | Overall Study |
|---|---|
| Mean | 49 ± 14 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 8 |
| Male | 6 |
| Race/Ethnicity, Customized(participants) | Overall Study |
|---|---|
| Caucasian | 11 |
| Hispanic | 2 |
| Black | 1 |
| Region of Enrollment(participants) | Overall Study |
|---|---|
| United States | 13 |
| United Kingdom | 1 |
| Myasthenia Gravis Foundation of America (MGFA) classification at Screening(participants) | Overall Study |
|---|---|
| IIa | 2 |
| IIb | 2 |
| IIIa | 8 |
| IVa | 2 |
| Number of MG crisis/exacerbation prior to Screening(Events) | Overall Study |
|---|---|
| Mean | 5 ± 6 |
| Prednisone use at Screening(participants) | Overall Study |
|---|---|
| Prednisone use | 7 |
| No prednisone use | 7 |
| Immunosuppression therapy other than prednisone at Screening(participants) | Overall Study |
|---|---|
| Yes | 7 |
| No | 7 |
3 further baseline measures are reported on the registry.
The record gives a start of Oct 2008, a primary completion of Mar 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2016, 5 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eculizumab
Alexion Pharmaceuticals, Inc. →